Seeking Products to Address Social Needs impacting Substance Use Disorders (SUD) (R41/R42 Clinical Trial Optional)
ID: 350387Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Award Range

$0 - $296K

Eligible Applicants

Small Businesses

Funding Category

Health

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/350387

Additional Information

http://grants.nih.gov/grants/guide/rfa-files/RFA-DA-25-047.html
Timeline
    Description

    The National Institutes of Health (NIH) is offering a funding opportunity titled "Seeking Products to Address Social Needs impacting Substance Use Disorders (SUD)," aimed at small business concerns (SBCs) to develop technologies that address health-related social needs influencing SUD, excluding alcohol use disorder. The initiative encourages the use of innovative technologies, such as telemedicine and mobile applications, to tackle issues like housing instability and food insecurity, ultimately improving access to treatment for individuals affected by SUD. Funding amounts include up to $306,872 for Phase I and $2,045,816 for Phase II, with applications due by March 14, 2026. Interested applicants can find more information and contact NIH Grants Information at grantsinfo@nih.gov for inquiries.

    Point(s) of Contact
    grantsinfo@nih.gov
    Files
    Title
    Posted
    RFA-DA-25-047-Full-Announcement.html
    RFA-DA-25-047.html
    The Department of Health and Human Services, through the National Institutes of Health (NIH) and the National Institute on Drug Abuse (NIDA), has released a funding opportunity titled "Seeking Products to Address Social Needs impacting Substance Use Disorders (SUD)." This initiative invites small business concerns (SBCs) to apply for Phase I, II, and Fast-Track Small Business Technology Transfer (STTR) grants, focusing on technologies that address health-related social needs (HRSN) influencing SUD, excluding alcohol use disorders. Key objectives include utilizing technology, such as telemedicine and mobile applications, to alleviate issues like housing instability and food insecurity, ultimately aiming to improve access to treatment for individuals with SUD. Funding up to $306,872 for Phase I and $2,045,816 for Phase II is available, with an anticipated total commitment of $1.3 million for four awards in fiscal year 2025. Applications are due by March 14, 2026, with a review process assessing technical feasibility, innovation potential, and the likely public health impact of the proposed products. The program emphasizes collaboration between public and private sectors to fill service gaps and improve outcomes for individuals battling SUD, highlighting the importance of addressing social determinants of health to support recovery and community integration.
    Similar Opportunities
    Seeking Products to Address Social Needs impacting Substance Use Disorders (SUD) (R41/R42 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity aimed at small business concerns (SBCs) to develop technologies that address health-related social needs impacting substance use disorders (SUD), excluding alcohol use disorder. This initiative, titled "Seeking Products to Address Social Needs impacting SUD," invites applications for Small Business Technology Transfer (STTR) grants under phases I and II, with a total funding amount of $1.3 million available for four awards in FY 2025. The focus is on leveraging innovative technologies, such as telemedicine and mobile health applications, to improve conditions like housing instability and food insecurity that influence SUD outcomes. Interested applicants must comply with specific eligibility criteria and application guidelines, with a submission deadline of March 13, 2026. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov or visit the full announcement at https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-25-047.html.
    Development of Medications to Prevent and Treat Substance Use Disorders and Overdose (UG3/UH3 - Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is preparing to release a Notice of Funding Opportunity (NOFO) aimed at supporting research for the development of medications to prevent and treat substance use disorders (SUDs) and overdose. This initiative will focus on preclinical and clinical research studies that can rapidly advance candidate interventions toward regulatory approval or clinical adoption, encouraging collaborative efforts among experts in various fields such as pharmacology, toxicology, and clinical trials. While applications are not currently being solicited, interested small businesses are encouraged to begin forming partnerships and developing projects in anticipation of the opportunity, with an estimated synopsis post date of August 15, 2025, and a projected award date of July 1, 2026. For further inquiries, potential applicants can contact Drew Townsend, Ph.D., at drew.townsend@nih.gov or by phone at 301-443-4577.
    Development of Interventions to Prevent and Treat Substance Use Disorders and Overdose (UG3/UH3 - Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Development of Interventions to Prevent and Treat Substance Use Disorders and Overdose (UG3/UH3 - Clinical Trial Optional)" aimed at supporting research into effective interventions for substance use disorders (SUDs) and overdose. This cooperative agreement encourages applications for preclinical and clinical studies focusing on pharmacotherapies, device-based treatments, digital therapeutics, and behavioral interventions, with the goal of advancing these interventions towards regulatory approval or clinical adoption. The funding amount can reach up to $3 million, and applications are due by 5:00 PM local time, with multiple submission cycles from October 2025 to August 2028. Interested applicants can find more information and contact NIH Grants Information at grantsinfo@nih.gov for inquiries.
    Device Based Treatments for Substance Use Disorders (UG3/UH3 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Device Based Treatments for Substance Use Disorders (UG3/UH3 Clinical Trial Optional)" aimed at accelerating the development of innovative devices to treat Substance Use Disorders (SUDs). The initiative seeks proposals that focus on advancing neuromodulatory or neurophysiological devices through various stages of the FDA approval process, with an emphasis on understanding treatment mechanisms and their efficacy. Eligible applicants include a diverse range of organizations, such as academic institutions, nonprofits, and tribal governments, with a maximum budget of $500,000 per year for the UG3 phase, which lasts up to two years before transitioning to the UH3 phase for an additional three years. Applications will open on November 18, 2023, with awards expected to commence by December 2023; interested parties can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Dynamic and Adaptable Infrastructure for Drug Development and Outreach to Aid the Research Community in Advancing Medication Repurposing and Repositioning Efforts for substance use disorders (SUDs) (U54 - Clinical Trials Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is announcing a funding opportunity titled "Dynamic and Adaptable Infrastructure for Drug Development and Outreach to Aid the Research Community in Advancing Medication Repurposing and Repositioning Efforts for Substance Use Disorders (SUDs)" under the U54 cooperative agreement mechanism. This initiative aims to establish a comprehensive drug development infrastructure that will support the research community in enhancing the substance use disorder drug development pipeline, focusing on the evaluation and validation of repurposed and repositioned drugs. The program is particularly important for fostering collaboration among researchers in pharmacology, toxicology, neuroscience, and related fields, providing essential services such as regulatory guidance and intellectual property consultations. The estimated total funding for this program is $2,500,000, with one award expected, and interested applicants are encouraged to prepare their proposals ahead of the estimated synopsis posting date on July 25, 2025, with applications anticipated to close by September 25, 2025. For further inquiries, potential applicants can contact Dr. Saravanan Karuppagounder at saravanan.karuppagounder@nih.gov or by phone at 301-480-9471.
    Mechanistic Research on Neuromodulation for Substance Use Disorders Treatment (R61/R33 Basic Experimental Studies with Humans Required)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Mechanistic Research on Neuromodulation for Substance Use Disorders Treatment," aimed at encouraging clinical research to explore novel non-invasive brain stimulation (NIBS) targets for treating substance use disorders (SUD). This initiative seeks applications for exploratory and developmental studies that will identify and validate neurobiological, cognitive, and behavioral responses to NIBS, with the goal of understanding mechanisms that could lead to reduced cravings and substance use. The NIH plans to allocate $1.5 million in funding for fiscal years 2024-2026, with an award ceiling of $500,000 per project phase, and key submission dates starting December 16, 2023. Interested applicants can find more information and guidelines at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Developing Digital Therapeutics for Substance Use Disorders (UG3/UH3 Clinical Trial optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Developing Digital Therapeutics for Substance Use Disorders (UG3/UH3 Clinical Trial optional)" aimed at advancing the development of Digital Therapeutics (DTx) for treating Substance Use Disorders (SUDs). This initiative seeks to support the creation of safe and effective clinical-grade digital platforms that can deliver therapeutic treatments, particularly for conditions that currently lack FDA-approved medications. The funding mechanism involves a two-phase cooperative agreement, with the UG3 phase focusing on initial milestones and design testing for up to two years, followed by the UH3 phase, which can extend for an additional three years upon successful completion of the UG3 phase. Eligible applicants include a diverse range of organizations, such as educational institutions, tribal governments, and community-based organizations. The application process opens on February 26, 2024, with multiple deadlines extending through late 2026. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov.
    Establishing a Center for the Advancement of Substance Use Disorder (SUD) Pharmacotherapeutics through Training and Preclinical Support
    National Institutes of Health
    The National Institutes of Health (NIH) is seeking to establish a Center for the Advancement of Substance Use Disorder (SUD) Pharmacotherapeutics through a Cooperative Agreement aimed at enhancing the development of new pharmacotherapeutics for SUD. The Center will focus on educating researchers in formal product development and providing technical and financial support for initial experiments, with an emphasis on creating a product development curriculum and fostering collaborations within the research community. This initiative is crucial for advancing drug addiction research and supporting the translation of innovative concepts into practical applications. The estimated total program funding is $3 million, with one award expected, and interested parties can contact Dr. Tam Nguyen at Tam.Nguyen@nih.gov or (301) 451-1203 for further information. The estimated synopsis post date is November 21, 2025, with applications expected to close on January 27, 2026, and the project anticipated to start on September 1, 2026.
    Device Based Treatments for Substance Use Disorders (UG3/UH3 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Institute on Drug Abuse (NIDA), is offering a funding opportunity aimed at accelerating the development of device-based treatments for Substance Use Disorders (SUDs) under the UG3/UH3 Cooperative Agreement mechanism. This initiative invites applications focused on both pre-clinical and clinical development of neuromodulatory devices, with the goal of advancing these technologies through the FDA approval process. The funding is structured in two phases: the UG3 phase supports milestone achievements for up to $500,000 annually over two years, while the UH3 phase provides continued funding for projects that successfully meet these milestones for an additional three years. Interested applicants can find more information and application guidelines at the provided NIH link, with the submission deadline set for August 13, 2026.
    Dynamic and Adaptable Infrastructure for Drug Development and Outreach to Aid the Research Community in Advancing Medication Repurposing and Repositioning Efforts for Substance Use Disorders (SUDs) (U54 - Clinical Trials Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting applications for a Specialized Center-Cooperative Agreement (U54) aimed at establishing a Dynamic and Adaptable Infrastructure for Drug Development and Outreach to enhance the research community's efforts in repurposing and repositioning medications for Substance Use Disorders (SUDs). The initiative seeks to support academic and biotech researchers by providing comprehensive drug development services, including regulatory guidance, intellectual property consultations, and technical support, while excluding clinical trials. This funding opportunity is critical for accelerating the drug development pipeline for SUDs, with NIH committing $2.5 million for one award in FY 2026, and applications are due by January 28, 2026. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov or visit the opportunity's webpage at https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-26-020.html.